269 related articles for article (PubMed ID: 26791786)
1. Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.
Serra KP; Peres RM; Sarian LO; Vassallo J; Pinto GA; Silva GR; Soares FA; da Cunha IW; Espinola J; Bento AM; Del Corso LM; Derchain S
Acta Histochem; 2016 Mar; 118(2):176-82. PubMed ID: 26791786
[TBL] [Abstract][Full Text] [Related]
2. COX2 overexpression is a prognostic marker for Stage III breast cancer.
Kim HS; Moon HG; Han W; Yom CK; Kim WH; Kim JH; Noh DY
Breast Cancer Res Treat; 2012 Feb; 132(1):51-9. PubMed ID: 21533532
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of Rsf-1 correlates with pathological type, p53 status and survival in primary breast cancer.
Ren J; Chen QC; Jin F; Wu HZ; He M; Zhao L; Yu ZJ; Yao WF; Mi XY; Wang EH; Wei MJ
Int J Clin Exp Pathol; 2014; 7(9):5595-608. PubMed ID: 25337201
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
Gándara-Cortes M; Vázquez-Boquete Á; Fernández-Rodríguez B; Viaño P; Ínsua D; Seoane-Seoane A; Gude F; Gallego R; Fraga M; Antúnez JR; Curiel T; Pérez-López E; García-Caballero T
Virchows Arch; 2018 Feb; 472(2):195-203. PubMed ID: 28825136
[TBL] [Abstract][Full Text] [Related]
6. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of molecular classification of breast invasive ductal carcinoma.
Muñoz M; Fernández-Aceñero MJ; Martín S; Schneider J
Arch Gynecol Obstet; 2009 Jul; 280(1):43-8. PubMed ID: 19082617
[TBL] [Abstract][Full Text] [Related]
8. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
[TBL] [Abstract][Full Text] [Related]
9. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
11. Clinico-pathological and molecular subtypes of male breast carcinoma according to immunohistochemistry.
Aşchie M; Bălţătescu GI; Mitroi A
Rom J Morphol Embryol; 2013; 54(3 Suppl):749-55. PubMed ID: 24322022
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
13. CD8⁺ cytotoxic T cell and FOXP3⁺ regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes.
Liu F; Lang R; Zhao J; Zhang X; Pringle GA; Fan Y; Yin D; Gu F; Yao Z; Fu L
Breast Cancer Res Treat; 2011 Nov; 130(2):645-55. PubMed ID: 21717105
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma.
Nakopoulou L; Mylona E; Papadaki I; Kapranou A; Giannopoulou I; Markaki S; Keramopoulos A
Pathobiology; 2005; 72(5):241-9. PubMed ID: 16374068
[TBL] [Abstract][Full Text] [Related]
16. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic characteristics and prognosis of glycogen-rich clear cell carcinoma of the breast.
Ma X; Han Y; Fan Y; Cao X; Wang X
Breast J; 2014; 20(2):166-73. PubMed ID: 24400866
[TBL] [Abstract][Full Text] [Related]
18. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
20. Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.
Berdel B; Nieminen K; Soini Y; Tengström M; Malinen M; Kosma VM; Palvimo JJ; Mannermaa A
BMC Cancer; 2012 Nov; 12():516. PubMed ID: 23148692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
